Eligible patients and consumers organisations

Human medicines European public assessment report (EPAR): INOmax, nitric oxide, Date of authorisation: 01/08/2001, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Insulin lispro Sanofi, insulin lispro, Date of authorisation: 19/07/2017, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Zykadia, ceritinib, Date of authorisation: 06/05/2015, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Arixtra, fondaparinux sodium, Date of authorisation: 20/03/2002, Revision: 38, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Varenzin, molidustat, Status: Authorised

Human medicines European public assessment report (EPAR): Heplisav B, hepatitis B surface antigen, Date of authorisation: 18/02/2021, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Biktarvy, bictegravir,emtricitabine,tenofovir alafenamide, Date of authorisation: 21/06/2018, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Erbitux, cetuximab, Date of authorisation: 29/06/2004, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Leflunomide Zentiva (previously Leflunomide Winthrop), leflunomide, Date of authorisation: 08/01/2010, Revision: 23, Status: Authorised